1130: Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI

Esperanza Pato¹, Lara Borrego-Sanz², Marta Domínguez³, Fernando Alonso⁴, Fayna Rodríguez-Gonazález⁵, Marta Tejera-Santana⁵, María del Mar Esteban-Ortega⁶, Isabel García-Lozano⁷, Lucia Martinez-Costa⁸, Samuel Gonzalez-Ocampo⁸, Maite Sainz de la Maza⁹, Aina Moll-Udina⁹, Zulema Plaza¹⁰, Alejandro Fonollosa-Calduch¹¹, Joseba Artaraz¹¹, Teresa Díaz-Valle¹², María Gurrea-Almela¹², David Diaz-Valle¹³ and Rosalía Méndez-Fernández¹³, ¹Hospital Clínico San Carlos, Rheumatology, Madrid, Spain, ²Hospital Clinico San Carlos, Ophthalmology, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Spanish Society of Rheumatology, Madrid, Spain, ⁵Hospital Doctor Negrín, Ophthalmology, Gran Canaria, Spain, ⁶Hospital Infanta Sofia, Madrid, Spain, ⁷Hospital Infanta Sofia, Ophthalmology, Madrid, Spain, ⁸Hospital Doctor Peset, Ophthalmology, Valencia, Spain, ⁹Hospital Clinic of Barcelona, Ophthalmology, Barcelona, Spain, ¹⁰Universidad Autónoma de Madrid, Madrid, Spain, ¹¹Hospital de Cruces, Ophthalmology, Bilbao, Spain, ¹²Hospital De Móstoles, Ophthalmology, Madrid, Spain, ¹³Hospital Clinico San Carlos, Madrid, Spain

Background/Purpose: Standardized and validated outcome measures of disease activity are lacking in the treatment and assessment of uveitis, making it difficult to compare efficacy and response to treatment. In 2014, this working group developed a composite index of ocular inflammatory activity: UVEDAI (1). The index was validated in a subsequent study conducted in 2019. The objective to this study was to determine the interobserver reliability and to demonstrate the sensitivity to change of the UVEDAI index in patients with anterior and non-anterior uveitis who undergo pharmacological treatment.

Methods: The design is an observational, longitudinal, prospective study in 7 Spanish hospitals. Patients over 18 years of age diagnosed with active uveitis were included. A complete baseline visit was performed by two ophthalmologists who determined ocular inflammatory activity with the UVEDAI index. Ophthalmologist 1 made a new visit at 4 weeks to determine the change in the level of uveal inflammatory activity using the UVEDAI index. The interobserver reliability analysis was performed by calculating the Intraclass Correlation Coefficient (ICC) with the values of the UVEDAI index obtained by ophthalmologist 1 and ophthalmologist 2 in the most inflamed eye at the baseline visit. Sensitivity to change in the UVEDAI index was assessed at 4 weeks from the start of pharmacological treatment by determining the Clinically Relevant Change defined as a change in UVEDAI of 0.8 points between the baseline visit and the 4-week visit.

Results: A total of 111 patients were included (54.1% male). The mean age at the time of the visit was 49.9 years. 36.9% of uveitis were idiopathic uveitis and 58.6% were anterior uveitis. The UVEDAI value was calculated from the score obtained in the 7 variables of the index. The mean value recorded in the most inflamed eye at the baseline visit by ophthalmologist 1 was 1.9 (1.2 anterior uveitis and 2.8 intermediate/posterior uveitis). The ICC for the UVEDAI value was 0.9 and when compared the mean UVEDAI values obtained by the two ophthalmologists for the most inflamed eye at the baseline visit no statistically significant differences were found (p-value >0.05), neither for the total sample nor differentiating by anatomical location. As for sensitivity of UVEDAI change, statistically significant differences (p-value=0.00) were found when comparing the mean values of the index measured by ophthalmologist 1 at the baseline visit and at 4 weeks, both in the overall sample and differentiating by anatomic location of uveitis. In all cases, the index value decreased significantly by more than 1 point at the 4-week visit after pharmacological treatment.

Conclusion: The interobserver reliability of the UVEDAI was high in the total sample and in the different variables. Furthermore, the index was sensitive in determining the change in inflammatory activity after treatment in both anterior and intermediate/posterior uveitis. We believe it is an index of activity that could be used both in routine clinical practice and in clinical studies and trials to compare results objectively

1: Pato-Cour E et al. Development of an activity disease score in patients with uveitis (UVEDAI). Rheumatol Int. 2017






E. Pato: None; L. Borrego-Sanz: None; M. Domínguez: None; F. Alonso: None; F. Rodríguez-Gonazález: None; M. Tejera-Santana: None; M. Esteban-Ortega: None; I. García-Lozano: None; L. Martinez-Costa: None; S. Gonzalez-Ocampo: None; M. Sainz de la Maza: None; A. Moll-Udina: None; Z. Plaza: None; A. Fonollosa-Calduch: None; J. Artaraz: None; T. Díaz-Valle: None; M. Gurrea-Almela: None; D. Diaz-Valle: None; R. Méndez-Fernández: None.